Age: 70.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Diplopia, Pupil dilation procedure, Vision blurred
Clinical narrative: I began having some vision blurriness which then became double vision; I began having some vision blurriness which then became double vision; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 13Apr2022 at 13:00 as dose 4 (booster), single (Lot number: FK9893) at the age of 70 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing); "RA (ankylosing spondylitis)" (unspecified if ongoing), notes: RA (ankylosing spondylitis); "RA (ankylosing spondylitis)" (unspecified if ongoing), notes: RA (ankylosing spondylitis); "Diabetes t2" (unspecified if ongoing), notes: Diabetes t2. Concomitant medication(s) included: LOSARTAN; EFFEXOR; LEVOTHYROXIN; REQUIP; ADDERALL. Past drug history included: Morphine, reaction(s): "Known allergies: Morphine", notes: Known allergies: Morphine; Codeine, reaction(s): "Known allergies: Codeine", notes: Known allergies: Codeine. Vaccination history included: BNT162b2 (Prev dose product: COVID 19,, Prev dose lot number: FF2590,, Prev dose administration time: 11:30 AM, Prev dose dose number: 3,, Prev dose vaccine location: Left arm), administration date: 14Oct2021, when the patient was 70-year-old, for COVID-19 Immunization; BNT162b2 (Prev dose product: COVID 19,, Prev dose brand: Pfizer,, Prev dose lot number BioNTech: EL9267,, Prev dose administration time: 10:45 AM, Prev dose dose number: 2,, Prev dose vaccine location: Left arm), administration date: 25Feb2021, when the patient was 69-year-old, for COVID-19 Immunization; BNT162b2 (Prev dose product: COVID 19,, Prev dose brand: Pfizer BioTech ,, Prev dose lot number: EL9265,, Prev dose administration time: 08:00 AM, Prev dose dose number: 1,, Prev dose vaccine location: Left arm), administration date: 29Jan2021, when the patient was 69-year-old, for COVID-19 Immunization. The following information was reported: VISION BLURRED (non-serious), DIPLOPIA (non-serious) all with onset 16Apr2022, outcome "not recovered" and all described as "I began having some vision blurriness which then became double vision". The event "i began having some vision blurriness which then became double vision" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of vision blurred, diplopia.  Additional information: If other vaccine in four weeks: No.  I began having some vision blurriness which then became double vision. I had my annual vision exam on 14Mar2022 which indicated a change was needed. I received my new glasses on 24Mar2022. I had no unusual vision issues at that time. My eyes were healthy. I returned to my optomologist regarding the double vision on 21Apr2022 A full exam revealed no change as far as the health of my eyes were concerned. However, it was very apparent I was seeing double. We went over the list of my medications & my recent lab reports. The only thing different was the 4th vaccination on 13Apr2022 & the onset of my vision distortion 2-3 days later. I have also reported this information to my primary care MD. They are in the process of referral to a neurologist. The optometrist believes the vision problem very well may be related to the vaccine I received on 13Apr2022. If COVID prior vaccination: No. If COVID tested post vaccination: No. Known allergies: Morphine, codeine. Other medical history: Hypertension, RA (ankylosing spondylitis), Diabetes t2   No follow-up attempts are possible. No further information is expected.